FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

OMB APP	ROVAL
OMD Number	2225 025

C	heck this box if no longer subject to
Se	ection 16. Form 4 or Form 5
ob	oligations may continue. See
In	etruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OWD 7 II I I	. O V/ \L							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

monuc																				
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol Acumen Pharmaceuticals, Inc. [ABOS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Doherty James J.					ABOS J									Director		10% Ov				
(Look) (First) (Middle)						2 Date of Earlingt Transportion (Manth/Day/Veer)								below)	(give title		Other (s below)	pecity		
(Last) (First) (Middle) C/O ACUMEN PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 01/06/2025								President and CDO						
1210-1220 WASHINGTON STREET, SUITE 210																				
1210-1220 WASHINGTON STREET, SUITE 210							4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)						,								Line)						
NEWTO	N M	IA	02465												Form filed by One Reporting Person Form filed by More than One Reporting					
-															Person					
(City)	(S	tate)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of	Security (Ins	tr. 3)		2. Transa Date	action	,	2A. Deem		3. 4. Securities Acquired (A) Transaction Disposed Of (D) (Instr. 3, 4)) or	5. Amou Securitie				7. Nature		
				(Month/D	ay/Ye	ay/Year) Execution I			Code (Instr. 5)		Of (D) (Instr. 3, 4 a		4 anu	Benefici	ally (D)		or Indirect	Beneficial Ownership		
					(Month/Day/Yea		ay/ rear	<u> </u>		(4) 0		or T		Reported	d			(Instr. 4)		
									Code	٧	Amount	(A) or (D)		Price	(Instr. 3					
Common Stock 01/06/						025 A 62,600 ⁽¹⁾ A \$0 62,600			D											
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
			(0	e.g., pı	uts,	cal	ls, warr	ants,	option	s, c	onverti	ble sec	uriti	es)						
1. Title of Derivative	2.	3. Transaction	3A. Deemed		Transaction Code (Instr.		5. Number		6. Date Exercisable and 7. Title a Expiration Date 7. Total				nount	8. Price of Derivative	9. Number		10. Ownership	11. Nature		
Security	Onversion or Exercise	Date (Month/Day/Year)	if any				Derivati	Derivative (N		(Month/Day/Year) Und			of Securities Underlying		Security	Securities		Form:	Beneficial	
(Instr. 3)	Derivative Acc					Securities Derivative Securities Acquired (Instr. 3 and 4)						urity (Instr. 5)		Beneficially Owned Following Reported			Ownership (Instr. 4)			
Security						(A) or Disposed														
						of (D) (Instr. 3, 4 and 5)										Transaction(s) (Instr. 4)				
														ount						
														mber						
				c	ode	v	(A)		Date Exercisab		Expiration Date	Title	of Sha	ares						
Employee								П												
Stock Option	\$1.85	01/06/2025			Α		93,300		(2)		01/06/2035	Common Stock	93	,300	\$0	93,300	0	D		
(right to												I Stock	1							

Explanation of Responses:

- 1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in three equal annual installments commencing one year after the grant date, subject to the Reporting Person's continuous service through each such vesting date.
- 2. The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

/s/ Derek Meisner, Attorney-in-

01/07/2025

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.